Shingrix In Recipients of Allogeneic Transplants

Abroad (travel likely)RecruitingPHASE2

Conditions

Bone Marrow Transplant · Stem Cell Transplant

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Colorado Hospital, Aurora, Colorado, United States
Contact: Study coordinator (Tori Rutherford, RN BSN) · tori.rutherford@childrenscolorado.org · 303-724-2454
Jonathan Gutman, MD (Sub-investigator)

Study leads

Myron Levin, MD
Principal Investigator
University of Colorado, Denver

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome

Immunodeficiency · Hematopoietic Stem Cell Transplantation

Abroad (travel likely)RecruitingPHASE2

Bethesda, United States

Orphan Indications for CD19 Redirected Autologous T Cells

Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL · Infants With Very High Risk KMT2A B-ALL · Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation

Abroad (travel likely)RecruitingPHASE2

Philadelphia, United States

Diagnostic Refinement and Educational Approaches in Managing Bone Marrow Transplantation

GVHD · Bone Marrow Transplant Complications

Abroad (travel likely)Recruiting

San Diego, United States

National Longitudinal Cohort of Hematological Diseases

Multiple Myeloma · Acute Myeloid Leukemia · Hemophilia

Abroad (travel likely)Recruiting

Tianjin, China